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OBJECTIVE—The aim of this study was to examine differences
between adolescents and adults in persistence of the beneﬁts of
intensive therapy 10 years after completion of the Diabetes
Control and Complications Trial (DCCT).
RESEARCH DESIGN AND METHODS—During the Epidemi-
ology of Diabetes Interventions and Complications (EDIC) study,
progression of retinopathy from DCCT closeout to EDIC year 10
was evaluated in 1,055 adults and 156 adolescents.
RESULTS—During 10 years of follow-up, HbA1c (A1C) was
similar between original intensive (INT) and conventional (CON)
groups and between former adolescents and adults. At EDIC year
10, adults in the former INT group continued to show slower
progression of diabetic retinopathy than those in the CON group
(adjusted hazard reduction 56%, P  0.0001), whereas in adoles-
cents this beneﬁcial effect had disappeared (32%, P  0.13).
Seventy-nine percent of observed differences in the prolonged
treatment effect between adults and adolescents at year 10 were
explained by differences in mean A1C during DCCT between
adolescents and adults (8.9 vs. 8.1%), particularly between INT
adolescents and adults (8.1 vs. 7.2%).
CONCLUSIONS—Prior glycemic control during DCCT is vital
for the persistence of the beneﬁcial effects of INT therapy 10
years later. Lowering A1C to as close to normal as safely possible
without severe hypoglycemia and starting as early as possible
should be attempted for all subjects with type 1 diabetes. These
results underscore the importance of maintaining A1C at target
values for as long as possible because the beneﬁts of former INT
treatment wane over time if A1C levels rise. Diabetes 59:
1244–1253, 2010
T
he Diabetes Control and Complications Trial
(DCCT) clearly demonstrated the beneﬁts of
intensive diabetes therapy aimed at lowering
blood glucose and HbA1c (A1C) as near to the
normal range as safely possible (1). A marked reduction
in retinopathy onset, retinopathy progression, and mi-
croalbuminuria was demonstrated in both the adult (18–39
years old at enrollment) and adolescent (13–17) cohorts
(2) treated with intensive therapy for a mean of 6.5 years.
The Epidemiology of Diabetes Interventions and Compli-
cations (EDIC) study, the observational follow-up of the
DCCT cohort (3), demonstrated that the differences in
complication occurrence and progression between former
intensive (INT) and conventional (CON) treatment groups
continued in adolescent and adult cohorts during the ﬁrst
4 years of EDIC (4,5) despite similar A1C in the treatment
groups during this time period. This phenomenon has been
termed “metabolic memory.”
The demonstration of metabolic memory suggests that
hyperglycemia contributes to the development of diabetes
complications over a long period of time and that halting
or reversing prior effects of hyperglycemia or prior bene-
ﬁts of improved glycemic control would also take an
extended period of time (6). Indeed, although the differ-
ence in retinopathy progression between former DCCT
INT and CON groups was recently shown to persist at least
10 years after the DCCT, the differences between the two
groups appeared to be waning (79% hazard reduction in
further retinopathy progression at EDIC year 4 vs. 53% at
year 10) (7).
We now present analyses of the EDIC year-10 retinopa-
thy data that were undertaken to determine whether
persistence of metabolic memory differed based on age at
the time of randomization in the DCCT (adults: 18–39
years vs. adolescents: 13–17) and, if so, what factors
contribute to this difference. Speciﬁcally, retinopathy re-
sults at year 10 of the EDIC study for the adult DCCT
cohort were compared with those of the adolescent co-
hort. The results from EDIC year 4 have previously been
reported for both the entire DCCT cohort (4) and for the
adolescent cohort (5) as have the retinopathy results for
the entire cohort at EDIC year 10 (7).
RESEARCH DESIGN AND METHODS
The design and methods of the DCCT have been reported previously (1). In
brief, the DCCT was a multicenter, randomized controlled trial comparing the
occurrence and progression of diabetes complications in subjects with type 1
diabetes randomized to INT or CON therapy. Eligible subjects between 13 and
39 years of age were randomized to INT or CON in either the primary
prevention arm (diabetes duration 1–5 years, no retinopathy, urine albumin
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early background retinopathy but no severe retinopathy, urine albumin 200
mg/day). When the DCCT ended in 1993, all subjects were instructed on INT
methods. In 1994, 1,375 of the DCCT participants enrolled in the EDIC study,
an observational follow-up study of the DCCT. A1C was determined by
high-performance liquid chromatography (8), in the same central laboratory
during DCCT and EDIC. Nephropathy evaluation, including serum creatinine
and a 4-h timed urine collection (to determine albumin excretion rate and
creatinine clearance) and fasting lipoprotein proﬁles were performed every
other year. Other annual evaluations included a standardized medical history
and physical examination, electrocardiogram, and a lower extremity neurop-
athy examination.
Ophthalmologic examination, visual acuity, and seven-ﬁeld fundus photog-
raphy were scheduled for each subject every four years and for the entire
cohort at EDIC years 4 and 10. Seven-ﬁeld stereoscopic fundus photography
was performed by trained and certiﬁed photographers and the photographs
were graded at a central reading center using the Early Treatment of Diabetic
Retinopathy Study (ETDRS) scale by graders masked to previous DCCT
treatment group assignment and A1C levels (9,10). Further 3-step progression
during EDIC, deﬁned as a 3-step progression from the ETDRS level at DCCT
closeout, is the primary outcome reported in this article.
Statistical analyses. To test for differences between groups, Wilcoxon
rank-sum tests were used for quantitative or ordinal data (11), and 
2
tests/Fisher exact tests were used for categoric data (12). The Mantel-
Haenszel method was used to calculate unadjusted odds ratios (ORs), as well
as stratiﬁed, adjusted ORs, with test-based conﬁdence limits (13). The
percentage reduction in the odds with INT versus CON therapy was computed
as (1  OR)  100. Generalized estimating equations (GEEs) with unstruc-
tured working correlation matrix (14) were used to test for differences in odds
reduction in further 3-step progression between EDIC years 4 and 10. All the
analyses were performed in the adult and adolescent cohorts (as enrolled at
DCCT baseline).
Interval censoring was observed because of the large intervals between
visits at which photographs were collected. Weibull proportional hazard
regression model was used because of its robustness in the presence of
heavily interval censored data (15,16). This model evaluated the effects of
prior treatment and other risk factors on the cumulative incidence of further
retinopathy progression from DCCT closeout through EDIC years 4 and 10. It
also evaluated the difference in treatment effect (metabolic memory) between
adults and adolescents by including the interaction term of treatment and
adult/adolescent in the model after adjustment for the other risk factors. The
Weibull model used all fundus photographs over all EDIC years in all patients.
Hazard ratios and P values were obtained from the Wald test. The overall
treatment effect and adult/adolescent effect were calculated using a 2 degrees
of freedom (df) likelihood ratio test. The proportion reduction in the magni-
tude of Madalla R
2 based on the value of the 
2 from the likelihood ratio test
was used to describe the proportion of variation in risk (difference in
metabolic memory between adults and adolescents) explained by the A1C
levels (13,17,18). All analyses were performed using SAS Version 9.1.
RESULTS
Subject follow-up. Of the 1,441 subjects (195 adoles-
cents) originally enrolled in the DCCT, 1,375 (175 adoles-
cents) were available at the conclusion of DCCT and
enrolled in the EDIC study; 1,208 subjects (170 adoles-
cents) were evaluated for retinopathy at EDIC year 4; and
1,211 subjects (156 adolescents) were evaluated at EDIC
year 10. The prevalence analyses reported here are limited
to the 1,211 subjects (156 adolescents) with a year-10
retinopathy evaluation.
The characteristics of these 1,211 subjects are summa-
rized in Table 1. Compared with adults, at DCCT baseline
adolescents were more likely to be from the primary
prevention cohort, have higher A1C, and have milder
retinopathy. They also had longer DCCT follow-up, higher
DCCT mean A1C, more severe retinopathy, and higher
albumin excretion rate (AER) levels at DCCT closeout. At
DCCT entry, there were no signiﬁcant differences between
INT and CON groups in any of the risk factors reported in
Table 1 in either the adult or adolescent cohort. At DCCT
closeout (equivalent to EDIC entry), treatment group
differences were seen in adults for the distribution of
retinopathy severity, the need for photocoagulation, and
microalbuminuria (AER 40 mg/24 h). In adolescents,
there was a similar (but nonsigniﬁcant) shift toward
milder levels in overall distribution of retinopathy severity
in the INT group (the risk of sustained 3-step progression
was signiﬁcantly reduced in the INT group in adolescents
during DCCT as reported earlier [2]), but there was no
difference in rates of photocoagulation, or AER levels.
Mean A1C levels during DCCT and across DCCT and EDIC
combined were signiﬁcantly lower in the INT group in
both adults and adolescents.
Treatment and metabolic outcomes. During the 10
years of EDIC follow-up, diabetes management was simi-
lar between former DCCT CON and INT groups. At EDIC
year 10, the majority of patients were using intensive
therapy, either continuous subcutaneous insulin infusion
or multiple daily insulin injections (Table 1). In addition,
more than half of the patients were self-monitoring blood
glucose more than three times a day except in the CON
adolescents (39%).
As shown in Table 1, there was no difference in A1C at
DCCT baseline between INT and CON groups in either
adolescents or adults, but the DCCT baseline A1C was
higher in the adolescents (9.6 vs. 9.0% in adults, P 
0.0001). As previously reported, the A1C was reduced in
the INT compared with the CON group during DCCT in
both age groups. However, adolescents had higher DCCT
mean A1C levels than the adult cohort in both the INT and
the CON group (Table 1, P  0.0001). During the EDIC
follow-up, mean A1C was similar between adults and
adolescents and between former INT and CON subjects
(INT adult: 8.0  1.1%; CON adult: 8.1  1.1%; INT
adolescent: 8.2  1.3%; CON adolescent: 8.2  2.1%, each
P  0.05).
Metabolic memory at EDIC years 4 and 10: preva-
lence analysis. As previously reported for both the entire
DCCT/EDIC cohort (4) and for the adolescent cohort (5),
the prevalence of further 3-step progression of retinopathy
from end of DCCT at EDIC year 4 was signiﬁcantly lower
in the former INT group than in the former CON group
despite similar A1C during this period; this was referred to
as metabolic memory. Figure 1 compares the metabolic
memory effect on further 3-step progression at 4 and 10
years of EDIC follow-up between adolescents and adults
who were free of scatter photocoagulation during DCCT
and had retinopathy evaluations at EDIC years 4 and 10. At
EDIC year 10, prolonged beneﬁcial treatment effect con-
tinued to be observed in the adult cohort. The prevalence
of further 3-step progression was 22% in the INT adults and
41% in the CON adults, with odds reduction of 57% (CI:
43–67%) in INT versus CON (P  0.0001); this is attenu-
ated compared with that at EDIC year 4 (odds reduction:
72%; 95% CI: 57–82%; P  0.0001). In the adolescent
cohort, however, there was no longer evidence of meta-
bolic memory. After 10 years of EDIC follow-up, 40% of
both the INT and CON adolescents had further retinopathy
progression (odds reduction: 0%; 95% CI: 88 to 49%; P 
0.9500) compared with 23% in CON and 8% in INT 4 years
after DCCT closeout (odds reduction: 72%; 95% CI: 17–90%,
P  0.0165). GEE analysis veriﬁed that the odds reduction
was signiﬁcantly different between EDIC years 4 and 10 in
both the adults (P  0.0329) and adolescents (P  0.0071).
Similar analyses were performed for the other retinop-
athy outcomes in the adolescents (Table 2) and adults
(Table 3). In the adult cohort, the odds for each of these
outcomes were signiﬁcantly lower in the INT group com-
N.H. WHITE AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, MAY 2010 1245pared with the CON group at DCCT closeout, at EDIC year
4, and at EDIC year 10 (odds reduction: 59–79%, 64–94%,
and 48–74%, respectively; all P  0.002), reﬂecting a strong
persistence of metabolic memory all the way through
EDIC year 10. In the adolescent cohort, however, meta-
bolic memory did not appear to be present for any of these
outcomes at EDIC year 10 and was present only for
3-step progression and severe nonproliferative diabetic
retinopathy at year 4.
Metabolic memory through EDIC years 4 and 10:
cumulative incidence analysis. To further assess meta-
bolic memory, we compared the cumulative incidence of
further 3-step progression during EDIC from the level at
DCCT closeout between former INT and CON treatment
groups in adolescents and adults. Separate Weibull pro-
portional hazards regression models were constructed in
adolescent and adult groups after adjustment for DCCT
primary prevention and secondary intervention cohort,
diabetes duration, A1C at DCCT entry, and retinopathy
severity at DCCT closeout. The models used evaluations
from all years in all eligible subjects, excluding 29 adults
and 7 adolescents who underwent scatter photocoagula-
tion in either eye during DCCT. Figure 2 shows the
estimated cumulative incidence for each treatment group
in adults and adolescents during the ﬁrst 4 years of EDIC
(A and B) and for the ﬁrst 10 years of EDIC follow up (C
and D). The Weibull model (Fig. 2) revealed a highly
signiﬁcant beneﬁcial effect of former INT in both adults
and adolescents 4 years after the end of DCCT (adjusted
hazard reduction 72%, P  0.0001 and 67%, P  0.01,
respectively). At EDIC year 10, this highly signiﬁcant
beneﬁcial effect of the former INT therapy was still
apparent (adjusted hazard reduction 56%, P  0.0001),
although attenuated compared with EDIC year 4, in the
adult cohort. In the adolescent cohort, the difference in
10-year cumulative incidence between INT and CON
TABLE 1
Characteristics of the 1,211 patients evaluated for retinopathy after 10 years of EDIC follow-up by age (adults vs. adolescents) and
DCCT treatment group (INT vs. CON)
Adolescents (n  156) Adults (n  1,055)
CON INT P* CON INT P*
n 83 73 532 523
At DCCT entry
Women (%) 56.6 46.6 0.2099 44.9 49.9 0.1053
Age (year) 14.8  1.4† 15.1  1.3† 0.0894 28.4  5.6† 28.9  5.7† 0.1957
Primary prevention cohort (%) 67.5† 54.8† 0.1044 48.7† 48.4† 0.9199
Duration of diabetes (year) 4.8  3.4 5.5  3.5 0.1481 5.9  4.2 6.1  4.3 0.4880
AER 40 mg/24 h (%) 7.2 8.2 0.8168 4.7 4.6 0.9321
Severity of retinopathy (%)
None 67.5† 54.8† 0.1765 48.7† 48.4† 0.0661
Microaneurysms only 21.7 37.0 29.0 34.8
Mild nonproliferative retinopathy 7.2 6.9 16.9 12.2
Moderate or severe nonproliferative
retinopathy 3.6 1.4 5.5 4.6
At EDIC entry‡
DCCT follow-up (year) 7.2  1.9† 7.5  1.9† 0.2088 6.2  1.6† 6.2  1.6† 0.4639
Severity of retinopathy (%)
None 8.4† 16.4† 0.1004 19.3† 30.2† 0.0001
Microaneurysms only 37.4 42.5 30.8 39.4
Mild nonproliferative retinopathy 27.7 28.8 27.7 20.5
Moderate or severe nonproliferative
retinopathy 26.5 12.3 22.3 9.9
Photocoagulation during DCCT (%)
Scatter, for severe retinopathy 4.8 4.1 0.8308 4.0 1.3 0.0084
Focal, for macular edema 1.2 1.4 0.9272 6.0 2.3 0.0025
AER 40 mg/24 h (%) 20.7† 20.8† 0.9876 10.8† 5.6† 0.0021
AER 300 mg/24 h (%) 4.9† 5.6† 1.0000 2.7† 1.0† 0.0613
Mean blood pressure (mmHg) 87.0  7.8 87.1  9.4 0.7572 88.4  8.8 88.9  8.5 0.3461
Elevated lipid (%)§ 12.1 5.5 0.1521 10.3 7.5 0.1005
Treatment at EDIC year 10 (%)
Continuous subcutaneous insulin infusion (pump)
or multiple daily injections 91.0 94.4 0.4223 92.4 96.9 0.0016
Self-monitoring of blood glucose 4 times/day 38.9 64.5 0.0018 61.1 55.8 0.0866
Glycemic control
A1C at DCCT eligibility (%) 9.5  1.8† 9.6  1.7† 0.4367 8.9  1.6† 9.0  1.5† 0.3439
DCCT mean A1C (%) 9.7  1.2† 8.1  1.1† 0.0001 8.9  1.2† 7.2  0.8† 0.0001
EDIC mean A1C up to year 10 (%) 8.2  2.1 8.2  1.3 0.8892 8.1  1.1 8.0  1.1 0.0713
DCCT-EDIC mean A1C up to year 10 (%) 8.8  1.0 8.2  1.1 0.0005 8.4  1.0 7.7  0.9 <0.0001
Data are means  SD unless otherwise indicated. *P values were based on Wilcoxon rank-sum test for quantitative or ordinal variables, or

2/Fisher exact test for categoric variables. †P  0.05 for comparison between adolescents and adults as a whole. ‡The baseline data in the
EDIC study were the same as the data at the end of the DCCT. §Elevated lipid is deﬁned as two consecutive reports of hypercholesterolemia
(LDL cholesterol 160 mg/dl) and/or hypertriglyceridemia (triglycerides 500 mg/dl) within 1 month during DCCT. Data in boldface are
statistically signiﬁcant.
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adjusted hazard reduction was less pronounced and no
longer signiﬁcant (32%, P  0.1399).
Risk factors for further retinopathy progression. Ta-
ble 4 examines the risk factors for further retinopathy
progression from DCCT closeout in a multivariate Weibull
regression model after combining the adult and adolescent
cohorts, and including the interaction of treatment (INT/
CON) and age (adult/adolescent). The model demon-
strates that the risk of further progression of retinopathy
increased signiﬁcantly with higher A1C level at DCCT
baseline (P  0.0001) and with higher mean blood pres-
sure and blood lipids at DCCT closeout (P  0.0001). Risk
was also associated with retinopathy severity at DCCT
closeout; patients with no retinopathy were at greater risk
of progression than those with microaneurysms only or
mild nonproliferative retinopathy but at lesser risk than
those with moderate or severe retinopathy.
As expected from previous results, after controlling for
other risk factors, the interaction between DCCT treat-
ment group (INT vs. CON) and age cohort (adolescent vs.
adult) remained signiﬁcant (P  0.0381), indicating that
the prolonged treatment effect on metabolic memory
differed by age. Likewise, this also indicates that the age
effect differed by treatment group. In the former INT
group, the hazard ratio (HR) of adolescent versus adult
was 1.7 (P  0.0078), indicating that INT adolescents had
70% higher risk of developing further 3-step progression in
retinopathy than the INT adults after adjustment for the
other risk factors. In the former CON group, however,
the HR was 1.0, indicating that CON adolescents had the
same risk of further retinopathy progression as CON
adults. The overall age (adolescent vs. adult) effect (P 
0.0001; df  2) and the overall treatment (INT vs. CON)
effect (P  0.0290; df  2) on retinopathy progression are
both signiﬁcant.
Relationship of hyperglycemia (A1C) to metabolic
memory difference between adults and adolescents.
To determine how much of the metabolic memory differ-
ence between adolescents and adults could be attributed
to the mean A1C levels achieved during DCCT and during
EDIC, separate Weibull models (as in Table 4) were
constructed with and without further adjustment for mean
A1C during DCCT or across DCCT and EDIC combined
(Table 5). These models show that 79% of the metabolic
memory difference between adults and adolescents (P 
0.0385) is attributed to the difference in mean A1C level
during DCCT (8.1 vs. 8.9 for the combined INT and CON
adults vs. adolescents, respectively), and 86% is attributed
to mean A1C difference across DCCT and EDIC combined
(8.0 vs. 8.4 for the combined INT and CON adults vs.
adolescents, respectively). Furthermore, given the differ-
ence in effect of age in the two treatment groups, as shown
in Table 4, similar Weibull models were constructed in the
INT and CON groups separately. In the INT group, 93% of
the observed difference in further retinopathy progression
between INT adults and adolescents (P  0.0155) was
explained by their mean A1C difference in DCCT (7.2 vs.
8.1%). However, in the CON group, the age effect was not
signiﬁcant (P  0.8848), indicating that CON adults and
CON adolescents had similar risk of further retinopathy
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A B
FIG. 1. Prevalence of further 3-step progression of retinopathy from the level at DCCT closeout at years 4 and 10 of EDIC, among patients free
of scatter laser photocoagulation during the DCCT and evaluated for retinopathy at EDIC year 10, by DCCT treatment group, for adolescents (A)
and for adults (B). Patients with prior scatter photocoagulation during DCCT (7 adolescents and 29 adults) were excluded. Odds reduction was
for intensive therapy (INT) compared with conventional therapy (CON). P values are from Mantel-Haenszel test and GEE models.
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mean A1C (9.7 vs. 8.9%).
To further examine the relationship of DCCT mean A1C
and retinopathy progression between the treatment
groups and adult/adolescent cohorts, separate Weibull
models were constructed in the INT and CON groups, after
further adjusting for A1C and the interaction of age (adult
vs. adolescent) and A1C. In each treatment group of each
age cohort, the risk of further retinopathy progression
increases with the DCCT mean A1C (adjusted HR per 10%
increase in A1C, e.g., 8–8.8, 1.5 or greater in each of the
four categories, P  0.003 in each).
Interestingly, in the INT group, but not in the CON
group, the association between DCCT mean A1C and risk
of retinopathy progression between DCCT closeout and
EDIC year 10 was stronger in adults than in adolescents
(Fig. 3). In the INT group, HRs per 10% increase in A1C
were 2.2 in adults and 1.5 in adolescents (and per 10%
decrease were 0.42 and 0.62, respectively) (P  0.0140). In
the CON group, corresponding HRs were 1.6 (increase)
and 0.59 (decrease), respectively, for adults and
adolescents.
DISCUSSION
The EDIC study demonstrated the surprising and unex-
pected phenomenon that the beneﬁts of improving glyce-
mic control on the development and progression of
retinopathy (4,5) persisted for 4 years after completion of
the DCCT, despite A1C levels that were similar in the two
former treatment groups (metabolic memory). The bene-
ﬁts of INT therapy and improved glycemic control were
substantial and similar in both adults and adolescents
during and for up to 4 years after the end of DCCT,
although adolescents had higher A1C as well as higher
rates of hypoglycemia (4,5) during DCCT.
In contrast, after 10 years of EDIC follow-up, the differ-
ent metabolic memory effect between adults and adoles-
cents presented here indicates that lower A1C during INT
intervention is an important determinant of the long-term
durability of its beneﬁts. Indeed, the difference in DCCT
mean A1C between adults and adolescents (8.1 vs. 8.9%)
explains 79% of the observed difference in the metabolic
memory effect on further retinopathy progression between
adults and adolescents after 10 years of EDIC follow-up.
Examining the A1C information further (Table 1), adoles-
cents started with a higher mean A1C level than adults at
DCCT enrollment in both the INT (9.6 vs. 9.0%) and CON
(9.5 vs. 8.9%) groups, and A1C remained higher in both
groups during the entire DCCT period (8.1 vs. 7.2% in INT;
9.7 vs. 8.9% in CON). It was only during the EDIC follow-up
that the mean A1C between adolescents and adults, as
well as between former INT and CON groups, converged.
Interestingly, although the CON adolescents had higher
A1C levels than the CON adults at DCCT enrollment (9.5
vs. 8.9%) and during the entire DCCT period (9.7 vs. 8.9%),
the hazard of further retinopathy progression did not differ
between CON adolescents and adults (adjusted hazard
reduction 1.0) 10 years after the end of DCCT after
adjustment for the other risk factors. However, with a
similar trend of higher A1C in INT adolescents than in INT
adults at DCCT enrollment (9.6 vs. 9.0%) and during DCCT
(8.1 vs. 7.2%), INT adolescents had signiﬁcantly higher risk
of retinopathy progression at 10 years compared with the
INT adults (adjusted hazard reduction 1.7, P  0.0078),
and 93% of the observed difference between the two age
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difference in DCCT mean A1C. Further analysis reveals
that INT adults are more sensitive to the A1C in DCCT
than the INT adolescents. Because INT adults have lower
A1C levels than the INT adolescents (7.2 vs. 8.1), a higher
sensitivity means a greater hazard reduction (58 vs. 38%
per 10% decrease in A1C) and a better treatment effect in
the INT adults. Therefore, the lower A1C during DCCT and
the higher sensitivity of retinopathy progression to the
DCCT mean A1C in the INT adults than in the INT
adolescents are likely the driving force of the long-term
durability of the beneﬁts of intensive therapy. That is, the
reduced ability to maintain glycemic levels as close to
normal as possible during DCCT in the INT adolescents
compared with INT adults and the lower sensitivity of the
INT adolescents to the A1C level during DCCT account for
the differing duration of metabolic memory in retinopathy
progression between adolescents and adults 10 years after
the end of DCCT. These data provide further compelling
evidence that the metabolic memory phenomenon is
largely driven by the prior levels of glycemic control
achieved. However, the mechanism for the metabolic
memory phenomenon is not well understood.
It should be noted that the persistent adverse effects of
hyperglycemia and the long-term beneﬁcial effects of
lowering glycemia on the development and progression
of complications have also been shown in animal models
of diabetes (19), in which it has also been termed meta-
bolic memory. One possible explanation for the metabolic
memory phenomenon is the slow accumulation, and sub-
sequent slow degradation, of advanced glycation end
products (AGEs) (20). Indeed, DCCT patients in the INT
group had lower concentrations of these AGEs in skin
collagen than did patients in the CON group (21). The
levels of these skin collagen AGEs were also shown to be
associated with the subsequent increase in progression of
retinopathy (and nephropathy) over the ﬁrst 10 years of
EDIC (22). The ﬁnding that the metabolic memory effect
appears to be waning between EDIC years 4 and 10 in the
entire cohort (7) and in the adult cohort (data reported
here) and is no longer present in the adolescent cohort
may be the result of a combination of clearance of the
long-lasting AGEs in the former CON group and the
accumulation of AGEs in the former INT group. There are
currently no direct data to prove this speculation, and
comparison of AGEs between adult and adolescent co-
horts of DCCT/EDIC is not currently available. However,
in the near future, measurements of skin ﬂuorescence may
provide data related to this speculation.
Another possible, but equally speculative, mechanism
by which prior glycemic control could have persistent
effects on development and progression of diabetes com-
plications is by epigenetic mechanisms. The phenomenon
of epigenetics refers to the chemical modiﬁcation of
cellular DNA or nuclear histones by factors in the internal
environmental milieu of the individual. Persistent changes
in key chromatin histone methylation could be induced by
hyperglycemia and result in sustained dysregulation (ex-
pression or repression) of gene expression for long peri-
ods of time. Epigenetic chromatin regulation of cellular
transcription can operate at both the local (that is, single
gene) level and at a global level over a period of time,
affecting multiple chromosomal domains. With the initia-
tion of the EDIC Epigenetics study, epigenetic modiﬁca-
tions of chromatin and alterations of gene expression that
could persist for a long period of time are being evaluated.
Despite the demonstrated differences in metabolic
memory at 10 years between adult and adolescent cohorts,
a few limitations must be acknowledged. First, the sample
size of the adolescent cohort is small relative to the adult
cohort, providing less power to demonstrate a signiﬁcant
effect should it exist in this age group. The small sample
size of the adolescent cohort will not affect our conclusion
related to the primary outcome of this study, further 3-step
progression from DCCT closeout, because the odds reduc-
tion at EDIC year 10 for adolescents was 0% (Fig. 1). We
cannot, however, rule out a type 2 error in other retinop-
athy outcomes, such as severe nonproliferative diabetic
retinopathy or worse, proliferative diabetic retinopathy, or
photocoagulation therapy (odds reduction: 46, 41, and
TABLE 3
Retinopathy outcomes during the ﬁrst 4 and 10 years of EDIC follow-up among adults free of that outcome at DCCT closeout who
had retinopathy evaluated at EDIC year 10
Retinopathy outcome*
DCCT closeout EDIC year 4§ EDIC year 10§
INT† CON†
Odds
reduction
(95% CI)‡ P INT CON
Odds
reduction
(95% CI)‡ P INT CON
Odds
reduction
(95% CI)‡ P
Three-step progression
from DCCT baseline
(%) 8.6 30.8 79 (70–85) 0.0001 11.4 26.7 64 (47–76) 0.0001 29.3 44.3 48 (31–61) 0.0001
n 523 532 431 330 475 368
SNPDR (%) 2.1 7.0 71 (43–86) 0.0002 2.2 10.2 81 (62–90) 0.0001 6.3 19.6 73 (58–82) 0.0001
n 523 532 464 449 512 495
PDR (%) 2.1 6.8 71 (41–85) 0.0002 1.7 9.3 83 (63–92) 0.0001 6.1 19.6 74 (59–83) 0.0001
n 523 532 464 450 512 496
CSME (%) 3.7 8.4 59 (28–76) 0.0014 0.4 7.5 94 (77–99) 0.0001 5.2 14.1 66 (46–79) 0.0001
n 516 510 450 429 497 468
Photocoagulation therapy
(focal or scatter) (%) 3.1 8.5 66 (38–81) 0.0002 1.0 6.4 85 (61–94) 0.0001 4.9 16.8 74 (59–84) 0.0001
n 523 532 507 487 507 487
*Patients with scatter photocoagulation after entry into the DCCT were counted as worse for retinopathy; those with focal photocoagulation
were counted as worse for macular edema. †INT is the former DCCT intensive group and CON is the former DCCT conventional group. ‡The
odds reduction is for intensive therapy compared with conventional therapy. §n at EDIC years 4 and 10 is limited to those free of particular
events at DCCT closeout. Data in boldface are statistically signiﬁcant.
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FIG. 2. Estimated cumulative incidence of further 3-step progression of retinopathy from DCCT closeout, by DCCT treatment group, through
EDIC year 4, for adolescents (A) and for adults (B); through EDIC year 10, for adolescents (C) and for adults (D). Subjects with prior scatter
photocoagulation during DCCT (7 adolescents and 29 adults) were excluded from analyses. Based on Weibull regression models adjusted for the
level of retinopathy at the end of the DCCT, primary vs. secondary cohort, the A1C value on entry to the DCCT, and diabetes duration at DCCT
baseline. Hazard reduction was for intensive therapy compared with conventional therapy.
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40%) engendered by the small sample size of adolescents.
Second, 18% of the adults and 25% of the adolescents who
enrolled in the DCCT did not have a retinopathy assessment
after 10 years of EDIC follow-up. Among these nonpartici-
pants, 5 adolescents and 33 adults died prior to EDIC year 10.
Further analyses (supplementary Table 1, available in an
online appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-1216/DC1) indicated that participants and
nonparticipants are similar in treatment group, age, sex,
diabetes duration, A1C, retinopathy levels, blood pressure,
and lipids in the adult cohort, and similar in the majority of
characteristics in the adolescent cohort except that the
10-year adolescent participants were slightly older at DCCT
entry (14.9 vs. 14.2 years; P  0.0034) and had worse
retinopathy (P  0.0301) at DCCT closeout. A possible
reason may be that patients with milder retinopathy pay less
attention to the monitoring of their retinopathy levels. How-
TABLE 4
Risk factor analysis for further retinopathy progression from DCCT closeout through EDIC year 10 Weibull model with interval
censoring
Covariate 
2 P HR (95% CI)*
At DCCT entry
Type 1 diabetes duration (year)† 3.2 0.0762 0.97 (0.94–0.02)
Primary vs. secondary cohort 0.0 0.9494 1.01 (0.77–1.32)
A1C level at DCCT eligibility (%) 38.0 0.0001 1.19 (1.12–1.25)
At EDIC entry‡
Retinopathy level
Microaneurysms only vs. no retinopathy 24.3 0.0001 0.53 (0.41–0.68)
Mild nonproliferative vs. no retinopathy 13.2 0.0003 0.58 (0.43–0.78)
Moderate or severe vs. no retinopathy 3.9 0.0496 1.41 (1.33–2.24)
Mean blood pressure (mmHg)†§ 18.6 0.0001 1.12 (1.06–1.17)
Elevated lipid (yes vs. no) 16.6 0.0001 1.72 (1.33–2.24)
Age (adolescent vs. adult) at DCCT enrollment 7.1 0.0079 —
DCCT treatment group (CT vs. INT) 1.7 0.1928 —
DCCT treatment group by age (adolescent vs. adult) 4.3 0.0381 —
Treatment effect (CON vs. INT)
In adult cohort: CON vs. INT (df  1) 64.3 0.0001 2.3 (1.9–2.9)
In adolescent cohort: CON vs. INT (df  1) 1.7 0.1927 1.4 (0.9–2.2)
Overall treatment effect: CON vs. INT (df  2) 7.1 0.0290
Age effect (adolescent vs. adult)
In INT group: adolescent vs. adult (df  1) 7.1 0.0078 1.7 (1.1–2.5)
In CT group: adolescent vs. adult (df  1) 0.0 0.9737 1.0 (0.7–1.4)
Overall age effect (adolescent vs. adult) (df  2) 65.3 0.0001
Model log likelihood 1,445.2
*HR is the ratio of hazard of retinopathy progression for a 1-unit increase in quantitative variables or change in status for dichotomous
variables if without notation. †HR is based on a 5-unit increase in type 1 diabetes duration (year)/mean blood pressure (mmHg). ‡The EDIC
entry data are the same as DCCT closeout data. §Mean blood pressure  2/3 diastolic blood pressure  1/3 systolic blood pressure. Elevated
lipid is deﬁned as two consecutive reports of hypercholesterolemia (LDL cholesterol 160 mg/dl) and/or hypertriglyceridemia (triglycerides
500 mg/dl) within 1 month during DCCT. Data in bold face are statistically signiﬁcant.
TABLE 5
Proportion of difference in metabolic memory between adults and adolescents after 10 years of EDIC follow-up explained by DCCT
and EDIC mean A1C
Model* Effect 
2 P
Proportion
explained (%)†
Overall
Unadjusted for A1C DCCT treatment group by age (adolescent
vs. adult) interaction effect‡
4.2 0.0385
Adjusted for DCCT mean A1C DCCT treatment group by age (adolescent
vs. adult) interaction effect
0.9 0.3448 79
Adjusted for DCCT-EDIC mean A1C DCCT treatment group by age (adolescent
vs. adult) interaction effect
0.6 0.4412 86
INT only§
Unadjusted for A1C Age effect (adolescent vs. adult) 5.9 0.0155
Adjusted for DCCT mean A1C Age effect (adolescent vs. adult) 0.4 0.5071 93
CON only§
Unadjusted for A1C Age effect (adolescent vs. adult) 0.0 0.8848
*All the models (unadjusted and adjusted) were from Weibull model after adjustment for all the risk factors in Table 3. A1C during DCCT
or across DCCT and EDIC combined was further adjusted in the adjusted models. †Proportion explained; see “Statistical analyses” section.
‡The interaction term of DCCT treatment group and age (adolescent vs. adult) measures the difference in prolonged treatment effect
(metabolic memory) between adults and adolescents. §Model used was from the same Weibull model in Table 3 but constructed within the
INT and CON group, respectively. Because there is no age (adolescent vs. adult) effect in the unadjusted model, there is no need to further
adjust for A1C.
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FIG. 3. Sensitivity of further retinopathy progression in EDIC to difference in DCCT mean A1C for adolescents and adults, for a 10% increase
in A1C in INT (A) and CON (B), and a 10% decrease in A1C in INT (C) and CON (D). Based on separate Weibull regression models in INT and
CON, adjusted for the level of retinopathy at the end of the DCCT, primary vs. secondary cohort, A1C value on entry to the DCCT, diabetes
duration at DCCT baseline, log transformation of DCCT mean A1C, age (adult vs. adolescent), and interaction of DCCT mean A1C and age.
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participants and nonparticipants, this observed slight imbal-
ance should not bias the conclusion in this study.
The DCCT/EDIC studies have shown that intensive
treatment directed at achieving blood glucose and A1C
levels as close to normal as safely possible without severe
hypoglycemia, and starting as early in the course of
diabetes as safely possible, is vital for achieving sustained
reductions of diabetic retinopathy. The results of the
present analyses reinforce the need to maintain A1C at
target values for as long as possible and demonstrate the
waning beneﬁts over time in the face of higher A1C levels.
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